Stuart Black
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, HIV/AIDS drug development and treatment, Hepatitis B Virus Studies, Systemic Lupus Erythematosus Research, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection(2016)173 cited
- → Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir(2015)76 cited
- → The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study(2016)76 cited
- → Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection(2014)36 cited
- → P0891 : Resistance analysis of virologic failures in Hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: The C-worthy study(2015)33 cited
- → P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325(2015)23 cited
- → Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin(2014)17 cited
- → Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a(2017)12 cited
- → Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse(2018)7 cited
- → In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A(2018)6 cited